美股A股
StockGist
Back
10-K2026-03-25· x-ai/grok-4.1-fast

ARMP · Armata Pharmaceuticals, Inc.

0001104659-26-034532

SEC filing

Summary

Armata Pharmaceuticals, Inc. (ARMP) reported a net loss of $173.8 million for FY 2025, ending December 31, 2025, compared to $18.9 million in FY 2024, primarily driven by a $121.0 million loss from the change in fair value of the Convertible Loan. Grant and award revenue declined 5.2% to $4.9 million from $5.2 million, reflecting reduced MTEC funding recognition. Operating expenses decreased 12.8% to $41.5 million, with R&D down 31.1% to $23.7 million due to completion of AP-PA02 and AP-SA02 Phase 2 trials, G&A down 5.9% to $12.4 million, offset by a $5.4 million impairment on lease ROU assets. Operating loss improved 13.7% to $36.6 million. Balance sheet shows $76.9 million total assets, $8.7 million cash, but $295.5 million liabilities including $153.9 million Convertible Loan, yielding $218.6 million stockholders' deficit. Cash used in operations was $25.8 million, offset by $25.6 million financing from term debt. Going concern doubt persists with cash runway insufficient for 12 months; Phase 3 for AP-SA02 planned H2 2026 contingent on funding.

Key takeaways

Full analysis

Performance Summary

Armata reported FY 2025 net loss of $173.8M, up from $18.9M in 2024, driven by $121.0M loss on Convertible Loan fair value change versus $31.4M gain prior year. Operating loss improved to $36.6M from $42.4M as expenses fell 12.8% to $41.5M. Revenue from grants dipped to $4.9M from $5.2M. EPS basic -$5 vs -$0.52. Balance sheet: assets $76.9M (down from prior), cash $8.7M, liabilities surged to $295.5M on $153.9M Convertible Loan.

Revenue Analysis

Grant and award revenue totaled $4.9M in 2025 vs $5.2M in 2024 (-5.2%), primarily from MTEC funding for AP-SA02 diSArm study. No other revenue sources disclosed. Funding tied to clinical costs; full MTEC award $26.2M, term to March 2026.

Margins & Profitability

No gross profit as pre-revenue biotech. Operating margin N/A; loss narrowed on lower R&D post-Phase 2 trials (AP-PA02 Tailwind, SWARM-P.a.; AP-SA02 diSArm). Impairment $5.4M hit; interest expense up to $16.6M on new debt.

Cash Flow & Balance Sheet

Operating cash use $25.8M (vs $37.6M 2024), investing $0.5M capex, financing $25.6M from $25.0M term debt. Net change -$0.7M; cash/restricted $19.2M end-period. Debt: $103.1M non-current term, $153.9M Convertible Loan; deficit -$218.6M. Going concern doubt; needs funding.

Outlook

Phase 3 AP-SA02 superiority trial H2 2026 for S. aureus bacteremia, per FDA EOP2 feedback; QIDP/Fast Track sought. AP-PA02 Phase 3 contingent on funding/partners. Sales agreement up to $100M; debt maturities extended to 2027/2029. Risks: liquidity, funding, clinical/regulatory hurdles.